Oct 29 (Reuters) - Immunovaccine Inc IMV.TO :
* Immunovaccine's vaccine candidate for respiratory syncytial virus is well
tolerated in volunteers in phase 1 clinical trial
* Says independent safety review committee has allowed the study to proceed to
its next step
* Source text for Eikon urn:newsml:reuters.com:*:nMKWjmCqHa
* Further company coverage IMV.TO